Completed PHASE1 INTERVENTIONAL 2-arm NCT05893576

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

A Relative Bioavailability Study of Single-dose, Randomized, Open-label, Single-period, Parallel Design of HRS9531 Injection Using Different Manufacturing Processes in Healthy Subjects

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions Type 2 Diabetes

Interventions HRS9531

Updated 4 times since 2023 Last updated: Oct 22, 2023 Started: May 15, 2023 Primary completion: Sep 4, 2023 Completion: Sep 4, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by Fujian Shengdi Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jul 2023 — Nov 2023 [monthly]

Recruiting PHASE1

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Shengdi Pharmaceutical Co., Ltd.

Data source: Fujian Shengdi Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China